text
"['\n1. 요약재무정보\n가. 요약연결재무정보\n\xa0 \xa0 \xa0 ( 단위 : 천원 )\n구분\n제 54 기 3분기\n제 53 기\n제 52 기\n연결재무상태표\n2024년 9월말\n2023년 12월말\n2022년 12월말\n\xa0[유동자산]\n76,901,713\n49,108,963\n52,925,045\n\xa0ㆍ현금및현금성자산\n25,029,191\n9,953,413\n12,084,861\n\xa0ㆍ단기금융상품\n600,000\n60,000\n50,000\n\xa0ㆍ매출채권\n33,338,793\n25,955,391\n23,416,318\n\xa0ㆍ금융자산\n2,899,611\n2,289,975\n7,805,040\n\xa0ㆍ기타자산\n11,883,059\n6,657,100\n7,057,892\n\xa0ㆍ재고자산\n3,151,059\n4,193,084\n2,510,934\n\xa0[비유동자산]\n49,972,404\n50,194,989\n53,581,480\n\xa0ㆍ금융자산\n5,554,788\n8,552,713\n11,987,234\n\xa0ㆍ유형자산\n33,198,177\n31,645,996\n26,819,937\n\xa0ㆍ사용권자산\n2,366,416\n1,054,042\n2,849,585\n\xa0ㆍ무형자산\n6,484,907\n6,762,615\n9,446,939\n\xa0ㆍ확정급여자산\n297,274\n-\n549,857\n\xa0ㆍ장기매출채권\n-\n-\n86,432\n\xa0ㆍ기타자산\n2,070,842\n2,179,623\n2,391,353\n자 \xa0산 \xa0총 \xa0계\n126,874,117\n99,303,952\n106,506,525\n\xa0[유동부채]\n74,823,142\n49,255,971\n54,587,759\n\xa0[비유동부채]\n6,992,119\n11,013,592\n11,293,282\n부 채 총 계\n81,815,261\n60,269,563\n65,881,041\n\xa0[지배기업 소유지지분]\n45,058,856\n39,034,389\n40,625,484\n\xa0ㆍ자본금\n16,935,634\n16,186,138\n15,624,677\n\xa0ㆍ자본잉여금\n58,584,407\n57,348,267\n56,190,556\n\xa0ㆍ기타자본항목\n1,428,919\n1,428,919\n1,428,920\n\xa0ㆍ기타포괄손익누계액\n(4,004,989)\n(4,011,252)\n(4,014,142)\n\xa0ㆍ이익잉여금(결손금)\n(27,885,115)\n(31,917,683)\n(28,604,527)\n\xa0[비지배지분]\n-\n-\n-\n자 본 총 계\n45,058,856\n39,034,389\n40,625,484\n종속기업및 관계기업 투자주식의 평가방법\n원가법\n원가법\n원가법\n연결손익계산서\n24.01.01~09.30\n23.01.01~12.31\n22.01.01~12.31\n\xa0매출액\n127,051,653\n135,981,756\n137,224,812\n\xa0영업손익\n4,580,035\n982,905\n7,770,473\n\xa0연결계속영업당기순이익\n4,054,167\n(2,364,589)\n6,506,743\nㆍ지배기업소유주지분손익\n4,054,167\n(2,364,589)\n5,369,963\nㆍ비지배기업소유주지분손익\n-\n-\n1,136,780\n\xa0당기순손익\n4,054,167\n(2,364,589)\n6,506,743\n\xa0주당순손익(원)\n123\n(75)\n172\n\xa0연결에포함된회사수\n1개\n1개\n1개\n※ 상기 요약 재무정보는 한국 채택국제회계기준(K-IFRS)에 따라 작성되었습니다.※ 2019년 1월 1일을 최초적용일로 하여 K-IFRS 제1116호를 최초 적용하였습니다.\n나. 연결재무제표의 연결에 포함된 회사\n종속기업명\n소유지분율\n소재지\n결산월\n업종\n셀론텍(주)\n100%\n한국\n12월\n바이오콜라겐 기반 치료재료 생산 및 판매\n다. 요약재무정보(별도)\n\xa0 \xa0 \xa0 ( 단위 : 천원 )\n구분\n제 54 기 3분기\n제 53 기\n제 52 기\n재무상태표\n2024년 9월말\n2023년 12월말\n2022년 12월말\n\xa0[유동자산]\n64,526,189\n39,160,374\n40,309,304\n\xa0ㆍ현금및현금성자산\n24,099,541\n9,242,839\n8,319,019\n\xa0ㆍ매출채권\n31,493,745\n24,420,883\n22,957,160\n\xa0ㆍ기타자산\n8,552,575\n4,955,711\n8,883,358\n\xa0ㆍ재고자산\n380,328\n540,941\n149,767\n\xa0[비유동자산]\n37,512,562\n40,529,879\n47,830,409\n\xa0ㆍ금융자산\n5,154,688\n8,352,613\n11,987,134\n\xa0ㆍ종속기업및관계기업투자\n28,349,160\n28,349,160\n28,349,160\n\xa0ㆍ유형자산\n272,232\n307,773\n374,120\n\xa0ㆍ사용권자산\n417,010\n600,765\n1,631,789\n\xa0ㆍ무형자산\n2,108,496\n2,035,242\n4,339,897\n\xa0ㆍ장기매출채권\n-\n-\n86,432\n\xa0ㆍ기타자산\n1,210,976\n884,326\n1,061,877\n자 \xa0산 \xa0총 \xa0계\n102,038,751\n79,690,253\n88,139,713\n\xa0[유동부채]\n65,086,573\n46,745,601\n50,314,992\n\xa0[비유동부채]\n275,852\n330,144\n1,185,573\n부 채 총 계\n65,362,425\n47,075,745\n51,500,565\n\xa0ㆍ자본금\n16,935,634\n16,186,138\n15,624,677\n\xa0ㆍ자본잉여금\n53,087,083\n51,850,942\n50,693,232\n\xa0ㆍ기타포괄손익누계액\n(4,004,989)\n(4,011,251)\n(4,014,142)\n\xa0ㆍ이익잉여금(결손금)\n(29,341,402)\n(31,411,321)\n(25,664,619)\n자 본 총 계\n36,676,326\n32,614,508\n36,639,148\n종속기업 투자주식의 평가방법\n원가법\n원가법\n원가법\n손익계산서\n24.01.01~09.30\n23.01.01~12.31\n22.01.01~12.31\n\xa0매출액\n114,297,783\n123,941,623\n127,511,300\n\xa0영업손익\n2,305,731\n(1,244,514)\n1,975,771\n\xa0당기순손익\n2,069,920\n(5,137,497)\n1,415,961\n\xa0주당순손익(원)\n63\n(163)\n45\n※ 상기 요약 재무정보는 한국 채택국제회계기준(K-IFRS)에 따라 작성되었습니다.※ 2019년 1월 1일을 최초적용일로 하여 K-IFRS 제1116호를 최초 적용하였습니다.\n']"
